Immunohistochemical staining was positive in 48% of the 50 prostate cancer specimens and 18% of the 50 benign controls, a ...
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease ...
Divarasib demonstrated best-in-class efficacy in Phase III trial, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer ...
Darolutamide with ADT significantly prolongs rPFS in metastatic prostate cancer while preserving tolerability. Read more here ...
Johanna S. Enke, MD, discusses safety findings from the Re-LuPSMA trial of lutetium Lu-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.
A systematic review and meta-analysis of eight studies found elevated serum TK1 in prostate cancer and an association with ...
Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the ...
An Oxford study of more than 6,000 blood proteins linked 12 to prostate cancer diagnosed over 15 years later, and seven to ...
The Big Pharma has already launched a phase 2 trial of JNJ-6143 at a 50 mg daily dose in around 100 patients with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced ...
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases ...
The UAE is turning into a proving ground for clinical AI, and the newest example sits in a pathology lab in Abu Dhabi.
Early-stage studies presented at ESMO reported promising activity for several experimental treatments for advanced prostate cancer. Johnson & Johnson’s oral JNJ-6143 produced substantial PSA declines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results